Supplementary Material for: Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data

<b><i>Background:</i></b> Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease (ILD). Characterizing health outcomes of IPF patients is challenging due to disease rarity. <b><i>Objective:</i></b> This study aimed to identify the burden of disease in patients newly diagnosed with IPF. <b><i>Methods:</i></b> Patients with ≥1 claim with an IPF diagnosis were identified from a United States healthcare insurer’s database (2000–2013). Patients with other known causes of ILD or aged &lt;40 years were excluded. Subgroups were compared based on the 2011 change in International Classification of Diseases, 9th Revision (ICD-9) definition of IPF and occurrence of IPF testing. The prevalence and incidence of preselected health conditions of clinical interest were estimated. <b><i>Results:</i></b> Median age of newly diagnosed patients (<i>n</i> = 7,298) was 62 years (54.0% male). Restricting to patients with IPF diagnostic testing did not substantially affect cohort characteristics, nor did ICD-9 IPF coding change. Mean follow-up was 1.7 years; 16.8% of patients died; and a substantial proportion of patients were censored due to end of health plan enrollment (50.7%) and other causes of ILD (19.6%). The incidence of pulmonary hypertension, lung cancer, and claims-based algorithm proxy for acute respiratory worsening of unknown cause was 22.5, 17.6, and 12.6 per 1,000 person-years, respectively. <b><i>Conclusions:</i></b> Patients with IPF had a high disease burden with a variety of health outcomes observed, including a high rate of mortality. Database censoring due to changes in enrollment or other ILD diagnoses limited follow-up. Altering cohort entry definitions, including IPF testing or ICD-9 IPF coding change, had little impact on cohort baseline characteristics.